Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Cameron West"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib to enhance tumor cell killing. GZ17-6.02 int
Externí odkaz:
https://doaj.org/article/3573b92758b84eecb29e3a3dfd3deca6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-
Externí odkaz:
https://doaj.org/article/837468e93d0e46f1a9917b694f144e3f
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We defined the lethal interaction between the novel therapeutic GZ17-6.02 and the standard of care combination of the MEK1/2 inhibitor trametinib and the B-RAF inhibitor dabrafenib in PDX isolates of cutaneous melanoma expressing a mutant B-RAF V600E
Externí odkaz:
https://doaj.org/article/6aa3d464e9f1493298d91bd326a49302
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/d050e1aeeb2f47a9bb8acc2cd1c8d522
Publikováno v:
JAAD Case Reports, Vol 15, Iss , Pp 80-81 (2021)
Externí odkaz:
https://doaj.org/article/d96a522e829b4916904195a8e90736f9
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate A
Externí odkaz:
https://doaj.org/article/b87b8c46f31548329f746ae9e97f01dc
Autor:
Cameron West, Darren Cronshaw
Publikováno v:
Journal of Spirituality in Mental Health. :1-21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e33546cd6959d8ee2149105c5ec9ad5f
https://doi.org/10.1080/19349637.2022.2094852
https://doi.org/10.1080/19349637.2022.2094852
Publikováno v:
Oncotarget
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. The present studies were performed to define its biology in renal carcinoma cells and to determine whether it interacted with axitinib to enhance tumor cell killing. GZ17-6.02
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ebde1bb1ece123aef80d35993d4f78
http://europepmc.org/articles/PMC8815785
http://europepmc.org/articles/PMC8815785
Publikováno v:
The American Journal of Dermatopathology. 44:276-278
Panfolliculomas (PF) are rare, benign, follicular tumors that differentiate toward multiple components of the hair follicle, and several variants have been described. We present a case of a rare pigmented PF presenting on actinically damaged skin in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cdc0a7436abfe8f712139cf08f1b0ba
https://doi.org/10.1097/dad.0000000000002120
https://doi.org/10.1097/dad.0000000000002120
Publikováno v:
Anti-cancer drugs. 33(5)
The drug GZ17-6.02 is undergoing phase I in solid tumor patients (NCT03775525). The present studies initially determined the impact of prolonged exposure of colorectal tumors to GZ17-6.02, and to determine whether GZ17-6.02 enhanced the efficacy of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98d0ef789f2eac57c304e026ae7fd2bb
https://pubmed.ncbi.nlm.nih.gov/35276694
https://pubmed.ncbi.nlm.nih.gov/35276694